RPG Life Sciences · NSE: RPGLIFE · BSE: 532983
Q4 FY23 results · Jan–Mar 2023
RPG Life Sciences reported revenue from operations of ₹118.49 crore (up 14.2% from Q4 FY22) and net profit of ₹10.35 crore (up 37.6% from Q4 FY22) for Q4 FY23 (Jan–Mar 2023), on a standalone basis.
| Item | Q4 FY23 | Q4 FY22 | YoY | Q3 FY23 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 118.49 | 103.80 | +14.2% | 130.60 | −9.3% |
| Other income | 1.84 | 1.26 | +46.0% | 0.51 | +260.8% |
| Total income | 120.33 | 105.06 | +14.5% | 131.11 | −8.2% |
| Profit before tax | 13.81 | 10.93 | +26.3% | 25.74 | −46.3% |
| Net profit for the period | 10.35 | 7.52 | +37.6% | 19.11 | −45.8% |
| EPS, basic (₹) | 6.26 | 4.55 | +37.6% | 11.56 | −45.8% |
| Net margin (%) | 8.7 | 7.2 | 14.6 |
Standalone
- Filed with BSE
- 09 May 2023, 15:23 IST
- Board meeting
- 28 Apr 2023
- Period
- 01 Jan 2023 to 31 Mar 2023
- Review status
- Audited
- Source
- XBRL filing on BSE